ARTS, an unusual septin, regulates tumorigenesis by promoting apoptosis - 18/06/22
, Jing Su a, b, c
, Zhuangzhuang Zheng a, b, c
, Jinlong Wei a, b, c
, Huanhuan Wang a, b, c
, Lingbin Meng d
, Ying Xin e, ⁎
, Xin Jiang a, b, c, ⁎ 
Abstract |
Apoptosis plays particularly important roles in tumorigenesis through various mechanisms. Apoptosis can be initiated by both extrinsic and intrinsic signals centered in and coming from the mitochondria. Antiapoptotic proteins promote tumor progression, and the occurrence and progression of tumors are closely related to antiapoptotic protein expression. As the only member of the septin gene family with proapoptotic function, apoptosis-related proteins in the TGF-β signaling pathway (ARTS) has received extensive attention for its unique structure. In contrast, unlike other known inhibitors of apoptosis protein (IAP) antagonists, ARTS exhibits a stronger tumor suppressor potential. Recent research has shown that ARTS can bind and inhibit XIAP and Bcl-2 directly or assist p53 in the degradation of Bcl-XL. Here, we review recent advances in the molecular mechanisms by which the proapoptotic protein ARTS, with its unique structure, inhibits tumorigenesis. We also discuss the possibility of mimicking ARTS to develop small-molecule drugs.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Apoptosis and tumorigenesis are inextricably linked. |
• | XIAP and Bcl-2 are highly expressed in various tumors. |
• | ARTS is the only proapoptotic protein that can antagonize both XIAP and Bcl-2. |
• | ARTS can cooperate with p53 to enhance the degradation of Bcl-XL. |
• | ARTS can promote apoptosis of a variety of cancer stem cells. |
Abbreviations : ARTS, FasL, TNF, TRAIL, TNFR, IAPs, SMAC/Diablo, Omi/HtrA2, MOM, ALL, XIAP, Bcl-2, IBM, Diap1, BIR, PtdInsP2, PtdInsP3, UPS, RING, Siah-1, Cyto c, BH, MOMP, MPTP, Apaf-1, CSCs, HSPCs, ISCs, HFSCs
Keywords : ARTS, Apoptosis, XIAP, Bcl-2, P53, ARTS mimetics
Plan
Vol 152
Article 113281- août 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
